Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Michael M Manos"'
Autor:
Elizabeth J. Short, Michael M Manos, Rachael C. Schindler, Sandra W. Russ, Susan I. Gross, Barbara A. Lewis, Rita Obeid, Maia M. Noeder, Laura E. Hlavaty
Publikováno v:
Language, speech, and hearing services in schools. 51(3)
Purpose Play is a critical aspect of children's development, and researchers have long argued that symbolic deficits in play may be diagnostic of developmental disabilities. This study examined whether deficits in play emerge as a function of develop
Autor:
Baginska J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nau A; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gomez Diaz I; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Giobbie-Hurder A; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Weirather J; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Vergara J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Abrecht C; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hallisey M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dennis J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Severgnini M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Huezo J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Marciello I; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rahma O; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Manos M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Brohl AS; Sarcoma Department and Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Bedard PL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Renouf DJ; Cancer and Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Sharon E; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Ott PA; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Buchbinder EI; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. stephen_hodi@dfci.harvard.edu.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Jan 18; Vol. 73 (1), pp. 17. Date of Electronic Publication: 2024 Jan 18.
Autor:
Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Pfaff KL; Department of Pathology, Brigham and Women's Hospital, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Turner MM; Department of Pathology, Brigham and Women's Hospital, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Manos M; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Ouyang O; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Rodig SJ; Harvard Medical School, Boston, MA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2023 Jun 01; Vol. 46 (5), pp. 192-196. Date of Electronic Publication: 2023 May 01.
Autor:
Groha S; Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard & MIT, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Alaiwi SA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Xu W; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Naranbhai V; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Nassar AH; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., El Zarif T; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wan G; Harvard Medical School, Boston, MA, USA.; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA., Rajeh A; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA., Adib E; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Nuzzo PV; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy., Schmidt AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Alessi JV; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy., Braun DA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Shukla SA; Broad Institute of Harvard & MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Keenan TE; Broad Institute of Harvard & MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Van Allen E; Broad Institute of Harvard & MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA., Awad MM; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy., Manos M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Rahma O; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Zubiri L; Massachusetts General Hospital, Boston, MA, USA., Villani AC; Broad Institute of Harvard & MIT, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Fairfax B; Department of Oncology, University of Oxford, Oxford, UK., Hammer C; Genentech, South San Francisco, CA, USA., Khan Z; Genentech, South San Francisco, CA, USA., Reynolds K; Harvard Medical School, Boston, MA, USA.; Division of Medical Oncology, Bartlett, Massachusetts General Hospital, Boston, MA, USA., Semenov Y; Harvard Medical School, Boston, MA, USA.; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA., Schrag D; Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kehl KL; Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman ML; Broad Institute of Harvard & MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Choueiri TK; Harvard Medical School, Boston, MA, USA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Gusev A; Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. alexander_gusev@dfci.harvard.edu.; Broad Institute of Harvard & MIT, Cambridge, MA, USA. alexander_gusev@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. alexander_gusev@dfci.harvard.edu.; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA. alexander_gusev@dfci.harvard.edu.
Publikováno v:
Nature medicine [Nat Med] 2022 Dec; Vol. 28 (12), pp. 2584-2591. Date of Electronic Publication: 2022 Dec 16.
Autor:
Tyan K; Harvard Medical School, Boston, MA 02115, USA., Abu-Shawer O; Harvard Medical School, Boston, MA 02115, USA.; Cleveland Clinic, Cleveland, OH 44195, USA., Baginska J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Severgnini M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Manos M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Vaitkevicius H; Department of Neurology, Brigham & Women's Hospital, Boston, MA 02115, USA.; Marinus Pharmaceuticals, Radnor, PA 19087, USA., Grover S; Harvard Medical School, Boston, MA 02115, USA.; Division of Gastroenterology, Department of Medicine, Brigham & Women's Hospital, Boston, MA 02115, USA., Hodi FS; Harvard Medical School, Boston, MA 02115, USA.; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Rahma OE; Harvard Medical School, Boston, MA 02115, USA.; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Publikováno v:
Immunotherapy [Immunotherapy] 2022 Aug; Vol. 14 (11), pp. 843-850. Date of Electronic Publication: 2022 Jun 13.
Autor:
Rahma OE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA osamae_rahma@dfci.harvard.edu.; Harvard Medical School, Boston, Massachusetts, USA., Tyan K; Harvard Medical School, Boston, Massachusetts, USA., Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Brohl AS; Sarcoma Department and Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Bedard PL; Division of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Renouf DJ; Cancer and Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Sharon E; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Hathaway E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Center for Immuno-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Cunningham R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Center for Immuno-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Manos M; Center for Immuno-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Severgnini M; Center for Immuno-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA., Rodig S; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Stephen Hodi F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Mar; Vol. 10 (3).
Autor:
Tyan K; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Baginska J; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Brainard M; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Severgnini M; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Manos M; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Haq R; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Buchbinder EI; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Ott PA; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Hodi FS; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA., Rahma OE; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA. Osamae_rahma@DFCI.harvard.edu.; Center for Immuno-Oncology, Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA. Osamae_rahma@DFCI.harvard.edu.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Aug; Vol. 70 (8), pp. 2209-2221. Date of Electronic Publication: 2021 Jan 22.
Autor:
Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Weirather JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Manos M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Quattrochi BJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Brennick RC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bowling P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bailey N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Magarace L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Haq R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Izar B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
Cancer medicine [Cancer Med] 2021 Apr; Vol. 10 (8), pp. 2627-2635. Date of Electronic Publication: 2021 Mar 15.
Autor:
Rogiers A; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia., Pires da Silva I; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia., Tentori C; FROM Fondazione per la Ricerca Ospedale Maggiore, Bergamo, Italy., Tondini CA; Papa Giovanni XXIII Hospital, Bergamo, Italy., Grimes JM; Columbia University Irving Medical Center, New York City, New York, USA., Trager MH; Columbia University Irving Medical Center, New York City, New York, USA., Nahm S; The Christie NHS Foundation Trust, Manchester, UK., Zubiri L; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Manos M; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Bowling P; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Elkrief A; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada., Papneja N; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada., Vitale MG; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Rose AAN; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Borgers JSW; Netherlands Cancer Institute, Amsterdam, The Netherlands., Roy S; Gustave Roussy and Paris-Saclay University, Villejuif, France., Mangana J; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Pimentel Muniz T; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Cooksley T; The Christie NHS Foundation Trust, Manchester, UK., Lupu J; Gustave Roussy and Paris-Saclay University, Villejuif, France., Vaisman A; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Saibil SD; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Butler MO; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Menzies AM; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore Hospital and Mater Hospital, Sydney, New South Wales, Australia., Carlino MS; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia., Erdmann M; Comprehensive Cancer Center Erlangen - EMN, University Medical Center Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany., Berking C; Comprehensive Cancer Center Erlangen - EMN, University Medical Center Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany., Zimmer L; University Hospital Essen & German Cancer Consortium, Partner Site, Essen, Germany., Schadendorf D; University Hospital Essen & German Cancer Consortium, Partner Site, Essen, Germany., Pala L; European Institute of Oncology, Milan, Italy., Queirolo P; Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Posch C; Technical University of Munich, German Cancer Consortium (DKTK), Munich, Germany., Hauschild A; University Hospital Schleswig-Holstein, Kiel, Germany., Dummer R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Haanen J; Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Netherlands Cancer Institute, Amsterdam, The Netherlands., Robert C; Gustave Roussy and Paris-Saclay University, Villejuif, France., Sullivan RJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Miller WH Jr; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada., Stephen Hodi F; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Suijkerbuijk KPM; University Medical Center Utrecht, Utrecht, The Netherlands., Reynolds KL; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Rahma OE; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Lorigan PC; The Christie NHS Foundation Trust, Manchester, UK.; University of Manchester, Manchester, UK., Carvajal RD; Columbia University Irving Medical Center, New York City, New York, USA., Lo S; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia., Mandala M; Unit of Medical Oncology, University of Perugia, Perugia, Italy., Long GV; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia georgina.long@sydney.edu.au.; Royal North Shore Hospital and Mater Hospital, Sydney, New South Wales, Australia.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jan; Vol. 9 (1).
Autor:
Grover S; Harvard Medical School, Boston, Massachusetts.; Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Dougan M; Harvard Medical School, Boston, Massachusetts.; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts., Tyan K; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts., Blum SM; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute at MIT and Harvard, Cambridge, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Ishizuka J; Departments of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut., Qazi T; Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, Ohio., Elias R; Hartford HealthCare Cancer Institute, Hartford, Connecticut., Vora KB; Harvard Medical School, Boston, Massachusetts., Ruan AB; Harvard Medical School, Boston, Massachusetts., Martin-Doyle W; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Manos M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Eastman L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Davis M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gargano M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Haq R; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Buchbinder EI; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Sullivan RJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Ott PA; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute at MIT and Harvard, Cambridge, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Hodi FS; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Rahma OE; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Publikováno v:
Cancer [Cancer] 2020 Aug 15; Vol. 126 (16), pp. 3758-3767. Date of Electronic Publication: 2020 Jun 22.